Covered recipient · General Payments record
JOSEPH YE
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$27,377.48
251 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $13,822.50 | 7 |
| Honoraria | $6,577.50 | 4 |
| Food and Beverage | $5,328.18 | 226 |
| Travel and Lodging | $857.05 | 5 |
| Education | $772.25 | 8 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20.00 | 1 |
By paying entity
PY2022 · entire year · sorted by reported total
Page 2 of 6; records 51–100 of 251 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JOSEPH YE
NPI 1700881422 · CMS profile ID 259019
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
OLYMPIA, WA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 6; records 51–100 of 251 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1700881422?year=2022&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JOSEPH YE, NPI 1700881422, CMS profile ID 259019. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 251 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700881422?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). JOSEPH YE, NPI 1700881422, CMS profile ID 259019. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 251 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700881422?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- JOSEPH YE, NPI 1700881422, CMS profile ID 259019, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 251 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1700881422?year=2022&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
251 matching records · $27,377.48 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 251.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $21.68 | 10/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 894461019 | CMS |
| Karyopharm Therapeutics Inc. | $2,445.00 | 10/11/2022 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 946520469 | CMS |
| Astellas Pharma US Inc | $7.72 | 10/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940294089 | CMS |
| E.R. Squibb & Sons, L.L.C. | $7.11 | 10/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932886785 | CMS |
| GlaxoSmithKline, LLC. | $20.22 | 10/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944818507 | CMS |
| PFIZER INC. | $22.36 | 10/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949478139 | CMS |
| Celgene Corporation | $23.43 | 10/06/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932886773 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.43 | 10/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 914639235 | CMS |
| Celgene Corporation | $22.52 | 10/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932886779 | CMS |
| Janssen Biotech, Inc. | $36.95 | 10/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 886724857 | CMS |
| Incyte Corporation | $1.33 | 09/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 943003027 | CMS |
| Incyte Corporation | $22.84 | 09/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 943003029 | CMS |
| CTI BioPharma Corp. | $27.58 | 09/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 933545107 | CMS |
| E.R. Squibb & Sons, L.L.C. | $9.45 | 09/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932886771 | CMS |
| Janssen Biotech, Inc. | $18.67 | 09/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 886724871 | CMS |
| Janssen Biotech, Inc. | $17.95 | 09/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 964350217 | CMS |
| E.R. Squibb & Sons, L.L.C. | $24.76 | 09/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932886765 | CMS |
| Celgene Corporation | $20.01 | 09/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932886761 | CMS |
| EISAI INC. | $12.63 | 09/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 908050415 | CMS |
| E.R. Squibb & Sons, L.L.C. | $4.79 | 09/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932886767 | CMS |
| Genentech USA, Inc. | $21.24 | 09/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950763873 | CMS |
| BeiGene USA, Inc. | $19.27 | 09/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940790033 | CMS |
| Astellas Pharma US Inc | $21.33 | 09/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940268233 | CMS |
| BeiGene USA, Inc. | $23.13 | 09/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940790035 | CMS |
| E.R. Squibb & Sons, L.L.C. | $4.83 | 09/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932886759 | CMS |
| Celgene Corporation | $24.32 | 09/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932886757 | CMS |
| PFIZER INC. | $28.62 | 09/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949327953 | CMS |
| Regeneron Healthcare Solutions, Inc. | $31.07 | 08/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927482347 | CMS |
| Novartis Pharmaceuticals Corporation | $18.54 | 08/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 894461017 | CMS |
| Regeneron Healthcare Solutions, Inc. | $15.84 | 08/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927482341 | CMS |
| Amgen Inc. | $34.12 | 08/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939850245 | CMS |
| JAZZ PHARMACEUTICALS INC. | $22.69 | 08/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 951329131 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $15.52 | 08/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 955883743 | CMS |
| Celgene Corporation | $0.79 | 08/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932886747 | CMS |
| Celgene Corporation | $21.22 | 08/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932886753 | CMS |
| Exelixis Inc. | $25.95 | 08/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932465683 | CMS |
| E.R. Squibb & Sons, L.L.C. | $23.04 | 08/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932886755 | CMS |
| ADC Therapeutics America, Inc. | $18.78 | 08/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1060940987 | CMS |
| E.R. Squibb & Sons, L.L.C. | $19.48 | 08/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932886741 | CMS |
| Seagen Inc. | $30.51 | 08/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 904104097 | CMS |
| Seagen Inc. | $4.02 | 08/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 904104101 | CMS |
| PFIZER INC. | $19.82 | 08/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949356105 | CMS |
| Seagen Inc. | $0.53 | 08/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 904104103 | CMS |
| Astellas Pharma US Inc | $85.95 | 08/09/2022 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940243821 | CMS |
| Lilly USA, LLC | $19.41 | 08/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918149049 | CMS |
| Seagen Inc. | $0.76 | 08/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 904104099 | CMS |
| Rigel Pharmaceuticals, Inc. | $1,170.00 | 08/05/2022 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 962277177 | CMS |
| Novartis Pharmaceuticals Corporation | $23.38 | 08/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 894461013 | CMS |
| ARRAY BIOPHARMA INC | $31.82 | 08/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949356107 | CMS |
| Exelixis Inc. | $24.78 | 08/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932464223 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,734,361.33 | 126 |
| PY2024 | Principal investigator | $1,347,808.17 | 60 |
| PY2023 | Principal investigator | $422,187.02 | 31 |
| PY2022 | Recipient | $2,830.85 | 2 |
| PY2022 | Principal investigator | $148,847.56 | 23 |
| PY2021 | Recipient | $23,810.46 | 5 |
| PY2021 | Principal investigator | $119,144.67 | 17 |
| PY2020 | Principal investigator | $35,689.74 | 15 |
| PY2019 | Principal investigator | $49,464.45 | 28 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
126 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $82.00 | 12/31/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY NETWORK LLC | A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE-FL-2) | No dispute reported | 06/30/2026 | 1202534821 |
| Principal investigator 1 | PFIZER INC. | $232.40 | 12/26/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228716793 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,803.00 | 12/22/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175415054 |
| Principal investigator 1 | ABBVIE INC. | $35,850.00 | 12/18/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202531148 |
| Principal investigator 1 | ABBVIE INC. | $16,782.08 | 12/04/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202526964 |
| Principal investigator 1 | ABBVIE INC. | $10,236.16 | 12/04/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202526968 |
| Principal investigator 1 | PFIZER INC. | $116.20 | 12/01/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228717141 |
| Principal investigator 1 | PFIZER INC. | $47,181.76 | 12/01/2025 | Non-covered Recipient Entity Vista Oncology Inc PS | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228719301 |
| Principal investigator 1 | PFIZER INC. | $10,175.00 | 12/01/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228806888 |
| Principal investigator 1 | PFIZER INC. | $100,815.00 | 12/01/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228807515 |
| Principal investigator 1 | PFIZER INC. | $29,849.28 | 12/01/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1228807521 |
| Principal investigator 1 | Incyte Corporation | $118.76 | 11/25/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS OF MARYLAND, PA | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240502047 |
| Principal investigator 1 | PFIZER INC. | $23,590.88 | 11/25/2025 | Non-covered Recipient Entity Vista Oncology Inc PS | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228719307 |
| Principal investigator 1 | PFIZER INC. | $232.40 | 11/24/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228716795 |
| Principal investigator 1 | ABBVIE INC. | $8,750.00 | 11/20/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202524794 |
| Principal investigator 1 | PFIZER INC. | $557.76 | 11/17/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228717571 |
| Principal investigator 1 | PFIZER INC. | $47,181.76 | 11/17/2025 | Non-covered Recipient Entity Vista Oncology Inc PS | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228719175 |
| Principal investigator 1 | PFIZER INC. | $23,590.88 | 11/12/2025 | Non-covered Recipient Entity Vista Oncology Inc PS | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228719105 |
| Principal investigator 1 | PFIZER INC. | $232.40 | 11/11/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228716799 |
| Principal investigator 1 | Incyte Corporation | $102,857.83 | 11/10/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS OF MARYLAND, PA | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240502043 |
| Principal investigator 1 | PFIZER INC. | $116.20 | 11/10/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228716619 |
| Principal investigator 1 | PFIZER INC. | $58,977.20 | 11/10/2025 | Non-covered Recipient Entity Vista Oncology Inc PS | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228719103 |
| Principal investigator 1 | ABBVIE INC. | $13,534.72 | 11/05/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202521605 |
| Principal investigator 1 | ABBVIE INC. | $12,614.40 | 11/04/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202520273 |
| Principal investigator 1 | ABBVIE INC. | $6,359.04 | 11/04/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202520275 |
| Principal investigator 1 | PFIZER INC. | $58,977.20 | 11/04/2025 | Non-covered Recipient Entity Vista Oncology Inc PS | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228719298 |
| Principal investigator 1 | Incyte Corporation | $642.00 | 10/30/2025 | Non-covered Recipient Entity CANCER CENTER FOR BLOOD DISORDERS A DIVISION OF AMERICAN ONCOLOGY PARTNERS P.A | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1240512049 |
| Principal investigator 1 | Novocure Inc. | $2,500.00 | 10/30/2025 | Non-covered Recipient Entity American Onocology Partners, PA | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma | No dispute reported | 06/30/2026 | 1250856687 |
| Principal investigator 1 | PFIZER INC. | $23,590.88 | 10/28/2025 | Non-covered Recipient Entity Vista Oncology Inc PS | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228719303 |
| Principal investigator 1 | PFIZER INC. | $813.40 | 10/27/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228717577 |
| Principal investigator 1 | PFIZER INC. | $23,590.88 | 10/22/2025 | Non-covered Recipient Entity Vista Oncology Inc PS | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228719099 |
| Principal investigator 1 | PFIZER INC. | $107,237.00 | 10/14/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228807510 |
| Principal investigator 1 | ABBVIE INC. | $13,012.48 | 10/09/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202514979 |
| Principal investigator 1 | ABBVIE INC. | $2,119.68 | 10/09/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202514981 |
| Principal investigator 1 | ABBVIE INC. | $25,153.28 | 10/09/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202514983 |
| Principal investigator 1 | Janssen Research & Development, LLC | $35,500.00 | 10/02/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175415076 |
| Principal investigator 1 | PFIZER INC. | $232.40 | 09/29/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228717313 |
| Principal investigator 1 | PFIZER INC. | $188,727.04 | 09/23/2025 | Non-covered Recipient Entity Vista Oncology Inc PS | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228719305 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $7,800.00 | 09/17/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192117289 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,950.00 | 09/17/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192117297 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,300.00 | 09/17/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192117307 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,170.00 | 09/17/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192117313 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $650.00 | 09/17/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192122055 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,170.00 | 09/17/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192122059 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,950.00 | 09/17/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192122065 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,250.00 | 09/17/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192122070 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,294.20 | 09/17/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192122075 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $9,812.40 | 09/17/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192122082 |
| Principal investigator 1 | PFIZER INC. | $348.60 | 09/15/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228716967 |
| Principal investigator 1 | PFIZER INC. | $58,977.20 | 09/09/2025 | Non-covered Recipient Entity Vista Oncology Inc PS | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228719173 |
| Principal investigator 1 | PFIZER INC. | $232.40 | 09/08/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228717575 |
| Principal investigator 1 | ABBVIE INC. | $26,773.76 | 09/04/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202509694 |
| Principal investigator 1 | ABBVIE INC. | $4,239.36 | 09/03/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202508286 |
| Principal investigator 1 | PFIZER INC. | $23,590.88 | 09/02/2025 | Non-covered Recipient Entity Vista Oncology Inc PS | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228719095 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,672.00 | 09/01/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175415018 |
| Principal investigator 1 | PFIZER INC. | $232.40 | 08/29/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228717145 |
| Principal investigator 1 | PFIZER INC. | $232.40 | 08/29/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228717311 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $66,291.50 | 08/27/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY NETWORK, LLC | a phase 3 multi center,open label,sponsor blinded,randomized study of azd0901 monotherapy compared with investigator s choice of therapy in second or later line adult participants with advanced metastatic gastric or gastroesophageal junction adenocarcinoma expressing claudin18 2 | No dispute reported | 06/30/2026 | 1185555063 |
| Principal investigator 1 | ABBVIE INC. | $23,232.29 | 08/25/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202505671 |
| Principal investigator 1 | PFIZER INC. | $47,181.76 | 08/25/2025 | Non-covered Recipient Entity Vista Oncology Inc PS | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228719177 |
| Principal investigator 1 | PFIZER INC. | $23,590.88 | 08/19/2025 | Non-covered Recipient Entity Vista Oncology Inc PS | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228718971 |
| Principal investigator 1 | PFIZER INC. | $92.96 | 08/18/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228717573 |
| Principal investigator 1 | PFIZER INC. | $232.40 | 08/13/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228716615 |
| Principal investigator 1 | PFIZER INC. | $205.75 | 08/11/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228716617 |
| Principal investigator 1 | PFIZER INC. | $23,590.88 | 08/11/2025 | Non-covered Recipient Entity Vista Oncology Inc PS | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228718969 |
| Principal investigator 1 | PFIZER INC. | $205.75 | 08/11/2025 | Non-covered Recipient Entity Vista Oncology Inc PS | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228719169 |
| Principal investigator 1 | PFIZER INC. | $23,590.88 | 08/07/2025 | Non-covered Recipient Entity Vista Oncology Inc PS | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228718974 |
| Principal investigator 1 | ABBVIE INC. | $7,087.36 | 08/06/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202502588 |
| Principal investigator 1 | PFIZER INC. | $92.96 | 08/06/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228717307 |
| Principal investigator 1 | ABBVIE INC. | $8,478.72 | 08/05/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202501474 |
| Principal investigator 1 | PFIZER INC. | $185.92 | 08/04/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228716797 |
| Principal investigator 1 | PFIZER INC. | $27,455.00 | 08/04/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228835218 |
| Principal investigator 1 | PFIZER INC. | $232.40 | 07/28/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228717309 |
| Principal investigator 1 | PFIZER INC. | $94,363.52 | 07/28/2025 | Non-covered Recipient Entity Vista Oncology Inc PS | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228719101 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,061.00 | 07/22/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175415031 |
| Principal investigator 1 | PFIZER INC. | $23.24 | 07/21/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228717143 |
| Principal investigator 1 | PFIZER INC. | $11,795.44 | 07/21/2025 | Non-covered Recipient Entity Vista Oncology Inc PS | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228719171 |
| Principal investigator 1 | PFIZER INC. | $139.44 | 07/17/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228716621 |
| Principal investigator 1 | PFIZER INC. | $23,590.88 | 07/17/2025 | Non-covered Recipient Entity Vista Oncology Inc PS | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228719226 |
| Principal investigator 1 | PFIZER INC. | $29,488.60 | 07/08/2025 | Non-covered Recipient Entity Vista Oncology Inc PS | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228719229 |
| Principal investigator 1 | PFIZER INC. | $116.20 | 07/07/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228716969 |
| Principal investigator 1 | PFIZER INC. | $29,488.60 | 07/07/2025 | Non-covered Recipient Entity Vista Oncology Inc PS | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228719231 |
| Principal investigator 1 | PFIZER INC. | $33,570.00 | 07/07/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228845910 |
| Principal investigator 1 | ABBVIE INC. | $17,530.88 | 07/02/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202494803 |
| Principal investigator 1 | ABBVIE INC. | $16,490.24 | 07/02/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | No dispute reported | 06/30/2026 | 1202496459 |
| Principal investigator 1 | ABBVIE INC. | $13,338.88 | 07/02/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202496471 |
| Principal investigator 1 | ABBVIE INC. | $28,565.76 | 07/02/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202496481 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,249.00 | 07/01/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175414965 |
| Principal investigator 1 | PFIZER INC. | $116.20 | 06/27/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228834997 |
| Principal investigator 1 | PFIZER INC. | $116.20 | 06/26/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228823131 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,151.86 | 06/10/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192122041 |
| Principal investigator 1 | ABBVIE INC. | $35,157.76 | 06/03/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202487799 |
| Principal investigator 1 | ABBVIE INC. | $21,153.10 | 06/03/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202487801 |
| Principal investigator 1 | ABBVIE INC. | $5,835.52 | 06/03/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202487803 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $16,607.45 | 05/16/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192122048 |
| Principal investigator 1 | Novocure Inc. | $2,591.82 | 05/15/2025 | Non-covered Recipient Entity American Onocology Partners, PA | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma | No dispute reported | 06/30/2026 | 1250856791 |
| Principal investigator 1 | AstraZeneca UK Limited | $54,007.40 | 05/08/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY NETWORK, LLC | Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL (ACRUE) | No dispute reported | 06/30/2026 | 1185555061 |
| Principal investigator 1 | ABBVIE INC. | $15,119.36 | 05/07/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202483175 |
| Principal investigator 1 | ABBVIE INC. | $27,480.08 | 05/07/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202483177 |
| Principal investigator 1 | ABBVIE INC. | $14,639.36 | 05/07/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202483249 |
| Principal investigator 1 | PFIZER INC. | $70,772.64 | 04/29/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228834275 |
| Principal investigator 1 | PFIZER INC. | $70,772.64 | 04/28/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228823073 |
| Principal investigator 1 | Incyte Corporation | $8,671.26 | 04/15/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS OF MARYLAND, PA | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240502039 |
| Principal investigator 1 | PFIZER INC. | $43,187.00 | 04/14/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228853311 |
| Principal investigator 1 | PFIZER INC. | $47,181.76 | 04/10/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228834269 |
| Principal investigator 1 | PFIZER INC. | $47,181.76 | 04/09/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228823078 |
| Principal investigator 1 | ABBVIE INC. | $16,195.78 | 04/03/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202470388 |
| Principal investigator 1 | ABBVIE INC. | $19,508.48 | 04/03/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202470393 |
| Principal investigator 1 | ABBVIE INC. | $4,513.28 | 04/03/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202470398 |
| Principal investigator 1 | PFIZER INC. | $70,772.64 | 03/28/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228835004 |
| Principal investigator 1 | PFIZER INC. | $70,772.64 | 03/18/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228823139 |
| Principal investigator 1 | ABBVIE INC. | $26,855.04 | 03/07/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | M22-003 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202459122 |
| Principal investigator 1 | ABBVIE INC. | $17,081.60 | 03/07/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202459126 |
| Principal investigator 1 | ABBVIE INC. | $3,084.80 | 03/07/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | M23-721 - Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202462012 |
| Principal investigator 1 | Novocure Inc. | $1,270.08 | 03/06/2025 | Non-covered Recipient Entity American Onocology Partners, PA | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma | No dispute reported | 06/30/2026 | 1250856789 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,589.00 | 02/20/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma | No dispute reported | 06/30/2026 | 1234181756 |
| Principal investigator 1 | PFIZER INC. | $52,857.00 | 02/18/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228853230 |
| Principal investigator 1 | Astellas Pharma Global Development | $13,490.00 | 02/13/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma | No dispute reported | 06/30/2026 | 1234181750 |
| Principal investigator 1 | Astellas Pharma Global Development | $9,672.00 | 02/13/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma | No dispute reported | 06/30/2026 | 1234181752 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,000.00 | 02/13/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma | No dispute reported | 06/30/2026 | 1234181754 |
| Principal investigator 1 | ABBVIE INC. | $13,578.24 | 02/06/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | M22-003 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202446731 |
| Principal investigator 1 | ABBVIE INC. | $5,506.56 | 02/06/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202446735 |
| Principal investigator 1 | ABBVIE INC. | $1,128.32 | 02/06/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY PARTNERS PA | M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202446738 |
| Principal investigator 1 | PFIZER INC. | $70,772.64 | 01/30/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228834992 |
| Principal investigator 1 | PFIZER INC. | $70,772.64 | 01/28/2025 | Non-covered Recipient Entity American Oncology Network Vista Oncology DivisionEast office | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228823125 |
| Principal investigator 1 | Incyte Corporation | $21,059.38 | 01/14/2025 | Non-covered Recipient Entity VISTA ONCOLOGY INC PS | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240615676 |